CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern Time. Mr. Petras, Jon Lyons, Senior Vice President and CFO, and Jason Peterson, Vice President, Investor Relations and Treasurer, will participate in meetings with investors during the conference.
A live webcast of Mr. Petras’ presentation and accompanying materials may be accessed via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health. A replay of the webcast will be available within 48 hours following the conclusion of the conference and archived on the Company's website.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.
INVESTOR RELATIONS CONTACTS:
Jason Peterson
Vice President, Investor Relations & Treasurer
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
Kristin Gibbs
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$16.16 |
Daily Change: | -0.17 -1.04 |
Daily Volume: | 848,717 |
Market Cap: | US$4.590B |
September 03, 2025 May 01, 2025 March 04, 2025 February 27, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load